Clinical Trials Browser

Completed × Head and Neck Neoplasms × zalutumumab × Clear all

NCT00542308 2023-08-03

Zalutumumab in Non-curable Patients With SCCHN

Phase 2 Completed

90 enrolled 10 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01054625 2023-08-03

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 1/2 Completed

31 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00093041 2023-06-28

Zalutumumab in Head and Neck Cancer

Phase 1/2 Completed

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00496652 2016-11-25

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Phase 3 Completed

Head and Neck Neoplasms

NCT00382031 2013-10-15

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Phase 3 Completed

286 enrolled 12 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell